Evidence review

Pelargonium for Cough

Pelargonium sidoides

The short answer

Promising clinical evidence

Possibly, for an uncomplicated cough with acute bronchitis or a cold, if you use a tested extract. Placebo-controlled trials of EPs 7630, mostly manufacturer-run, found coughs eased sooner over a week; Cochrane rated that evidence low quality. A 2026 Swiss trial against usual care found no faster recovery. EMA accepts pelargonium only as a traditional cold remedy; NICE lists it for self-care from age 12. Stop at once for yellow skin or eyes, dark urine, or unusual tiredness, and see a doctor for breathing trouble, coughing blood, or a cough lasting over 3 weeks.

8 key studies reviewed

Updated November 16, 2026

Key points

  1. 01

    Most trials tested one extract

    Nearly all research used EPs 7630, a Schwabe root extract sold as Umckaloabo or Kaloba. Results do not automatically apply to unlabeled or generic pelargonium products.

  2. 02

    Placebo trials suggest modest benefit

    In adults and children with acute bronchitis, liquid EPs 7630 eased cough and other symptoms faster than placebo over a week. Cochrane rated that evidence low quality.

  3. 03

    Usual care was not beaten in 2026

    In 332 Swiss adults with bronchitis, EPs 7630 did not shorten time to half symptoms versus usual care. Antibiotic use was numerically lower but not statistically significant.

  4. 04

    Regulators stay cautious

    EMA accepts pelargonium only as a traditional remedy for common cold symptoms from age 3. NICE lists it for acute cough self-care from age 12 with limited evidence of some benefit.

  5. 05

    Stop if liver signs appear

    Rare liver injury reports led to label warnings. Stop at once and see a doctor with yellow skin or eyes, dark urine, abdominal pain, or unusual tiredness.

Pelargonium root extract may ease an acute cough a little, but the benefit is modest, the best evidence is of low quality, and almost all of it comes from one manufacturer’s product. In placebo-controlled trials of EPs 7630, an aqueous-ethanolic root extract made by Dr Willmar Schwabe and sold as Umckaloabo in Germany and Kaloba in Britain, adults and children with acute bronchitis improved faster over a week than those given a placebo (dummy) medicine. Cochrane’s 2013 review by Timmer and colleagues concluded that the liquid extract may relieve bronchitis symptoms while rating that evidence low quality. England’s National Institute for Health and Care Excellence (NICE) lists pelargonium as a self-care option for acute cough from age 12 with limited evidence of some benefit. The European Medicines Agency (EMA) was not persuaded that the trials prove efficacy and accepts pelargonium root only as a traditional herbal medicine for symptoms of the common cold.

A cough that comes with a cold or chest infection usually clears up on its own within three to four weeks, according to the UK National Health Service (NHS) and NICE. Some coughs are dry and tickly; others are chesty and bring up mucus. Acute bronchitis is a short-lived lower airway infection, usually viral, that often starts after a cold and features a cough that may be dry at first and then productive. Pelargonium sidoides is a South African grassland plant; the medicine is made from its tuberous roots, not from window-box “geraniums.” Brands matter: EPs 7630 is the extract tested in nearly all trials, while other pelargonium products may use different extracts or none that have been studied against placebo. Ivy leaf syrups and thyme–ivy combinations are the other well-studied herbal options for a chesty cough.

This page goes through the placebo-controlled bronchitis trials and who ran them, what Cochrane, NICE, and EMA concluded, how a 2026 Swiss trial against usual care fared, which products and doses were tested, and who should avoid pelargonium, especially because of rare liver injury reports. Nothing here is medical advice. A cough with breathing difficulty, chest pain, several days of fever, or coughing up blood, or one that lasts more than three weeks, needs a doctor rather than a herbal remedy.

02 The trials

Key studies

The trials and reviews that carry the most weight for this question, with the product and dose each one tested. Results apply to the preparation studied.

  1. Timmer et al., 2013 (Cochrane)

    Cochrane systematic review of double-blind randomized controlled trials versus placebo or other treatment

    Who
    8 trials analyzed of 10 eligible; 746 adults and 819 children with acute bronchitis in the main analyses
    What and how much
    Pelargonium sidoides extract (Umckaloabo / EPs 7630), liquid or tablets
    How long
    Literature searched to April 2013; most bronchitis trials lasted 7 days

    Liquid extract may relieve symptoms of acute bronchitis in adults and children (low-quality evidence); tablets were not consistently effective. Evidence for sinusitis and the common cold was very low quality. Adverse events were more common than with placebo, but none were serious. All trials came from the manufacturer’s program in Ukraine and Russia, and a funnel plot raised suspicion of publication bias.

  2. Matthys and Heger, 2007

    Randomized, double-blind, placebo-controlled, multicenter trial; co-authored by a Schwabe researcher

    Who
    217 adults aged 18–66 with acute bronchitis (108 EPs 7630, 109 placebo)
    What and how much
    EPs 7630 solution, 30 drops three times daily, versus matching placebo
    How long
    7 days

    The Bronchitis Severity Score (cough, sputum, chest pain on coughing, chest sounds, and breathlessness) fell by 7.6 points with EPs 7630 and 5.3 with placebo (95% CI for the difference 1.6–3.1; p < 0.0001). Individual symptoms including cough improved more than with placebo. Only minor, short-lived adverse events were recorded; none were serious.

  3. Kamin et al., 2010 (liquid, ages 1–18)

    Randomized, double-blind, placebo-controlled, multicenter trial

    Who
    200 patients aged 1–18 years with acute bronchitis outside the strict indication for antibiotics
    What and how much
    EPs 7630 drops by age (3 × 10 drops ages 1–6; 3 × 20 ages 6–12; 3 × 30 ages 12–18) versus placebo
    How long
    7 days

    The Bronchitis Severity Score improved by 3.4 points with EPs 7630 versus 1.2 with placebo (p < 0.0001). Treatment outcome, satisfaction (77.6% versus 25.8%), onset of effect, and time in bed also favored the extract. Tolerability was similar; all adverse events were judged non-serious. Current EU labels do not recommend oral use under age 3.

  4. Kamin et al., 2010 (tablet dose-finding)

    Randomized, double-blind, placebo-controlled, four-arm dose-finding trial at 16 Ukrainian centers

    Who
    400 patients aged 6–18 years with acute bronchitis
    What and how much
    EPs 7630 film-coated tablets at 30, 60, or 90 mg daily versus matched placebo
    How long
    7 days

    Change in the Bronchitis Severity Score was significantly better with 60 mg and 90 mg daily than with placebo, with no relevant difference between those two doses; cough, sputum, and chest sounds improved most. Onset of effect was faster and bed rest shorter. Tolerability matched placebo in all groups. Cochrane later found tablets less consistently effective than the liquid across adult and child bronchitis trials.

  5. Kardos et al., 2022

    Meta-analysis of randomized, placebo-controlled trials; three co-authors employed by Schwabe

    Who
    2,195 participants from 11 trials (3 in children/adolescents with bronchitis, 3 in adults with bronchitis, 5 in adults with common cold)
    What and how much
    EPs 7630 versus placebo
    How long
    Outcomes assessed at day 7 in bronchitis trials and day 5 in cold trials

    Complete cough remission at day 7 occurred in 26.0% of adults with bronchitis on EPs 7630 versus 6.3% on placebo, and in 18.0% versus 5.5% of children. A ≥50% fall in cough intensity was about twice as likely with the extract in bronchitis. In colds, benefits at day 5 were smaller. Quality-of-life scores also favored EPs 7630. The analysis was manufacturer-affiliated.

  6. Bourqui et al., 2026 (PHYTOBRONCH)

    Pragmatic, open-label, randomized controlled trial versus usual care; authors declared no competing interests

    Who
    332 adults with a first consultation for acute bronchitis and cough of up to 8 days, at 36 Swiss family practices and 5 walk-in clinics (155 EPs 7630, 177 usual care)
    What and how much
    Kaloba EPs 7630 liquid, 30 drops three times daily for 7 days (up to 21 days if cough persisted), versus usual care
    How long
    Follow-up over about 3 weeks; enrollment August 2023–April 2025

    No difference in days to a 50% fall in Acute Bronchitis Severity Score symptoms (adjusted coefficient 0.05; 95% CI −0.13 to 0.23; p = 0.578). Antibiotic use was 17.4% with EPs 7630 versus 25.2% with usual care (adjusted risk ratio 0.78; 95% CI 0.49–1.26; p = 0.309). Mild adverse events were more frequent with EPs 7630 (32.3% versus 21.5%).

  7. Lizogub et al., 2007

    Randomized, double-blind, placebo-controlled trial

    Who
    103 adults with common-cold symptoms of 24–48 hours’ duration
    What and how much
    EPs 7630 solution, 30 drops (1.5 ml) three times daily, versus placebo
    How long
    Up to 10 days

    By day 10, 78.8% on EPs 7630 were judged clinically cured versus 31.4% on placebo, and time off work averaged 6.9 versus 8.2 days. Cochrane could include only one cold trial and rated the evidence very low quality, noting benefit at day 10 but not day 5. EMA accepts pelargonium for cold symptoms on traditional use, not proven efficacy.

  8. Teschke et al., 2012

    Causality re-assessment of spontaneous hepatotoxicity reports using the CIOMS liver scale

    Who
    15 spontaneous cases of primarily suspected pelargonium-related liver injury
    What and how much
    Pelargonium sidoides preparations used for colds and other respiratory infections
    How long
    Case reports accumulated before the 2012 analysis

    In none of the 15 cases was pelargonium a highly probable or probable cause. Confounding diagnoses and poor data quality were common, including missing tests for viral hepatitis. German regulators had still required liver warnings after receiving about 30 reports by 2012, including one transplant; EU and UK labels keep the stop-and-seek-help wording.

03 Evidence

What the research shows

Promising clinical evidence

Our rating for Pelargonium for Cough, based on the studies below.

The case for pelargonium in cough rests mainly on EPs 7630 trials in acute bronchitis. In a representative adult study, Matthys and Heger (Current Medical Research and Opinion 2007) randomized 217 adults aged 18 to 66 to 30 drops of EPs 7630 solution or placebo three times a day for seven days. The Bronchitis Severity Score (BSS), covering cough, sputum, chest pain on coughing, chest sounds, and breathlessness, fell by 7.6 points with pelargonium and 5.3 with placebo, a difference whose 95% confidence interval was 1.6 to 3.1 points. The corresponding author worked for Schwabe. In children and adolescents, Kamin and colleagues (International Journal of Clinical Pharmacology and Therapeutics 2010) treated 200 patients aged 1 to 18 for seven days with age-banded drops; the BSS improved by 3.4 points against 1.2 on placebo. A separate dose-finding tablet trial by Kamin and colleagues (Acta Paediatrica 2010) in 400 patients aged 6 to 18 found benefit at 60 mg and 90 mg daily but not clearly at 30 mg. EMA’s herbal committee set a higher bar for clinical relevance, at least a 4-point BSS difference in adults and 3 in children, and judged that none of the bronchitis trials reached it; it also noted that the trials came from the same investigators and the manufacturer, mostly in Ukraine and Russia.

Pooled analyses favor EPs 7630 but share those limitations. Cochrane’s Timmer review analyzed eight of ten eligible trials: three in 746 adults and three in 819 children with acute bronchitis suggested benefit for the liquid preparation but not consistently for tablets, on low-quality evidence, with a funnel plot that raised suspicion of publication bias. Evidence for sinusitis and the common cold was very low quality. Kardos and colleagues (Multidisciplinary Respiratory Medicine 2022), including three Schwabe researchers, pooled 11 placebo-controlled trials with 2,195 participants: by day 7, cough had stopped completely in 26.0% of adults with bronchitis on EPs 7630 against 6.3% on placebo, and in 18.0% against 5.5% of children. For the common cold, Lizogub and colleagues (Explore 2007) reported that 78.8% of 103 adults taking 30 drops three times daily were judged cured by day 10 against 31.4% on placebo, but Cochrane could include only that one cold trial and rated the evidence very low quality.

Real-world results are less clear. In the PHYTOBRONCH trial, Bourqui and colleagues (npj Primary Care Respiratory Medicine 2026) randomized 332 adults with acute bronchitis in Swiss primary care and walk-in clinics to Kaloba EPs 7630 or usual care, without a placebo. There was no difference in the time taken for symptoms to fall by half. Antibiotic use was 17.4% with pelargonium and 25.2% with usual care, a difference that was not statistically significant, and mild adverse events were more frequent with pelargonium (32.3% against 21.5%). The authors declared no competing interests and called for larger trials of any antibiotic-sparing role. That pragmatic result does not erase the placebo-controlled findings, but it shows that in everyday practice, against whatever doctors usually offer, a faster recovery has not been demonstrated.

Guideline and regulator judgments sit between enthusiasm and skepticism. NICE’s 2019 acute cough guideline tells clinicians that some people may wish to try pelargonium from age 12 as self-care with limited evidence of some benefit, alongside honey and certain over-the-counter cough medicines, while stressing that most acute coughs settle within three to four weeks without antibiotics. The NHS cough page likewise names pelargonium for ages 12 and over, with limited evidence. EMA’s May 2024 monograph, by contrast, lists only traditional use for symptomatic treatment of the common cold, explicitly not well-established use for bronchitis, and its assessment report concludes that efficacy in moderate acute upper respiratory infections has not been adequately proven. A fair summary is that a tested EPs 7630 product may modestly speed recovery from acute bronchitis cough on low-quality, mostly manufacturer-run evidence, that usual-care comparison has so far been negative, and that unlabeled “pelargonium” supplements should not be assumed to match the trial product.

04 In practice

How it was taken in studies

The product with the trial record is EPs 7630, a liquid extract of Pelargonium sidoides root (drug-to-extract ratio 1:8–10, 11% ethanol) or corresponding dry extracts, made by Schwabe. In Germany the best-known brand is Umckaloabo; in the UK, Kaloba tablets (20 mg dry extract each) and Kaloba syrup hold traditional herbal registrations for symptoms of upper respiratory infections such as sore throat, cough, and blocked or runny nose. Most adult bronchitis trials used 30 drops (about 1.5 ml) of the solution three times a day for seven days. EMA’s 2024 monograph gives, for the liquid, 1.4 ml three times a day for adolescents over 12 and adults, 0.9 ml for children aged 6 to 12, and 0.4 ml for children aged 3 to 5; for dry extracts, 20 mg three times a day in adults, with lower daily totals in children, and liquids only under age 6. The UK Kaloba syrup leaflet gives 7.5 ml three times a day from age 12 and 5 ml from 6 to 12, continued for two to three days after symptoms ease but for no longer than two weeks.

Start early if you try it: cold trials enrolled people within 24 to 48 hours of symptoms, and bronchitis trials within days of a new cough. EMA advises seeing a doctor if symptoms last longer than a week while taking a pelargonium medicine, or if they worsen. Pelargonium can sit alongside the self-care the NHS recommends: rest, plenty of fluids, paracetamol (acetaminophen) or ibuprofen for aches, and hot lemon and honey for anyone over 1 year old. Antibiotics do not help most viral coughs, and NICE advises against routinely offering them for acute bronchitis. Do not take two pelargonium products at once, including a single-herb syrup together with a combination cold remedy that already contains the root.

Match the product to the evidence and the label. Prefer a licensed medicine that names Pelargonium sidoides root extract and, where possible, EPs 7630, rather than an unlabeled “geranium” or “umcka” blend of unknown strength. Liquid drops contain alcohol; EMA requires ethanol labeling, and alcohol-free syrups or tablets may suit children, people who avoid alcohol, and anyone with a history of liver disease. Age limits differ: EU traditional products may start at 3, UK Kaloba products at 6, and NICE’s self-care advice at 12, so follow the leaflet for your country. For a dry, tickly cough, honey or demulcent herbs that coat the throat are traditional alternatives; for a chesty cough, ivy leaf and thyme–ivy combinations have their own trial pages on this site.

05 Caution

Before you try pelargonium

In trials, side effects have mostly been mild and short-lived. Cochrane found adverse events more common with pelargonium than with placebo, but none serious. Stomach upset (pain, nausea, heartburn, diarrhea), mild gum or nose bleeding, and skin rashes are the reactions listed on UK Kaloba labels; serious allergic reactions with facial swelling, breathlessness, and a fall in blood pressure are very rare. In PHYTOBRONCH, 32.3% of people on EPs 7630 reported adverse events against 21.5% on usual care, all mild. Stop the product and get urgent help for swelling of the face or throat, widespread hives, or difficulty breathing.

Liver injury is the main debated risk. By June 2012 Germany’s drug regulator, BfArM, had received about 30 spontaneous reports of liver problems linked with pelargonium products, including hepatitis and jaundice, and one patient who needed a liver transplant; 19 of the 30 had been taking other medicines. BfArM required warnings on German products. Teschke and colleagues (Regulatory Toxicology and Pharmacology 2012) re-examined 15 cases and found none in which pelargonium was a probable cause, citing poor data and other explanations. EMA’s monograph still lists hepatotoxicity and hepatitis with frequency not known, and UK Kaloba leaflets say to stop immediately and seek medical advice for yellowing of the eyes or skin, nausea, vomiting, dark urine, abdominal pain, unusual tiredness, or loss of appetite. Do not take pelargonium if you have severe liver disease. LiverTox, the US National Institutes of Health liver-injury reference, has no dedicated pelargonium chapter.

EMA does not recommend pelargonium in pregnancy or breastfeeding because safety has not been established, and UK labels say the same. Oral use under age 3 is not recommended in the EU monograph, because a cough or fever at that age needs medical advice; preparations for children under 6 should be liquids. UK Kaloba products start at age 6. People with a past allergic reaction to a pelargonium product should not take it again. Formal drug interactions have not been reported; one study found no effect on penicillin V blood levels. Tell your pharmacist what you take, especially other medicines that can affect the liver, and avoid doubling up with combination cold products that already contain pelargonium.

Most coughs settle on their own, but some signs call for a doctor rather than another bottle. The NHS advises seeing a GP for a cough lasting more than 3 weeks, unexplained weight loss, or a weakened immune system, and asking for urgent help if the cough is very bad or quickly getting worse, you feel very unwell, you have chest pain, you find it hard to breathe, or you are coughing up blood. NICE adds seeking help if symptoms worsen rapidly or significantly, do not improve after three to four weeks, or the person becomes systemically very unwell, and lists higher-risk groups who should contact a clinician early, including people with significant heart, lung, kidney, liver, or neuromuscular disease or weakened immunity. The Kaloba leaflet also advises seeing a doctor for fever lasting several days, shortness of breath, or blood in the sputum. For children, get urgent care for struggling to breathe, blue or gray lips, unusual sleepiness, or any cough in a baby under 3 months.

06 Questions

Frequently Asked Questions

It may help a little, if you use the tested extract. Placebo-controlled trials of EPs 7630 found faster improvement in cough and bronchitis scores over a week in adults and children, and Cochrane concluded the liquid may relieve acute bronchitis symptoms while rating the evidence low quality. A 2026 Swiss trial found no faster recovery than usual care. Our guide to herbs for cough compares other options, including ivy leaf for cough.

Umckaloabo (Germany) and Kaloba (UK) are brand names for Schwabe’s EPs 7630 root extract, the product used in nearly all the trials. Generic or unlabeled “pelargonium” or “umcka” supplements may use different extracts or strengths and should not be assumed to match the trial results. Choose a licensed medicine that names Pelargonium sidoides root extract when you can.

Both have modest, imperfect evidence for a chesty cough. Ivy leaf has two manufacturer-run placebo trials of the Prospan extract EA 575; see our ivy leaf for cough review. Thyme and ivy (Bronchipret) reduced daytime coughing fits more than placebo in 361 adults. Pelargonium has more bronchitis trials but the same manufacturer-funding problem, and EMA accepts it only on traditional use for cold symptoms.

It depends on age and the product. EMA’s traditional monograph allows oral use from age 3 (liquids only under 6); UK Kaloba products are licensed from age 6; NICE’s self-care advice applies from age 12. Trials in children with bronchitis reported mostly mild side effects. Do not use it under 3 without medical advice, and never treat a young child’s fever or breathing difficulty with a herbal remedy alone.

Rarely, perhaps. German regulators received about 30 liver reports by 2012, including one transplant, and required label warnings, although a causality re-analysis by Teschke and colleagues could not confirm pelargonium as the probable cause in the cases they examined. Stop at once and see a doctor for yellow skin or eyes, dark urine, abdominal pain, or unusual tiredness. Do not take it with severe liver disease.

No. Most acute coughs and bronchitis cases are viral and do not need antibiotics anyway; NICE says antibiotics make little difference to how long symptoms last. Laboratory antibacterial effects of the extract are far weaker than antibiotics. The 2026 Swiss trial saw slightly less antibiotic use with EPs 7630, but the difference was not statistically significant. Pneumonia and other bacterial infections need proper medical treatment. Echinacea is another cold-season herb with its own evidence and limits.

See a doctor if a cough lasts more than 3 weeks, if you are losing weight for no reason, or if you have a weakened immune system. Get urgent help for chest pain, difficulty breathing, coughing up blood, a cough that is quickly getting worse, or feeling very unwell. EMA and Kaloba leaflets also advise medical review if symptoms last more than a week on treatment, or if fever lasts several days. Our cough herb guide lists the same NHS and NICE red flags.

07 References

Sources

These references support the claims on this page. They are not an endorsement of any product. The pelargonium monograph carries its own full source list.

  1. Pelargonium sidoides extract for treating acute respiratory tract infections

    Cochrane Database of Systematic Reviews (PubMed 24146345), 2013

    Timmer et al.: eight trials analyzed; liquid may relieve acute bronchitis in adults (746) and children (819), low-quality evidence; tablets less consistent; sinusitis and cold very low quality; more adverse events but none serious; possible publication bias.

  2. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study

    Current Medical Research and Opinion (PubMed 17288687), 2007

    Matthys and Heger: 217 adults, 30 drops three times daily for seven days; BSS fell 7.6 vs 5.3 points; only minor adverse events; Heger affiliated with Schwabe.

  3. Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis - a randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots

    International Journal of Clinical Pharmacology and Therapeutics (PubMed 20197012), 2010

    Kamin et al.: 200 patients aged 1–18; BSS improved 3.4 vs 1.2 points; satisfaction 77.6% vs 25.8%; all adverse events non-serious.

  4. Efficacy and tolerability of EPs 7630 in patients (aged 6–18 years old) with acute bronchitis

    Acta Paediatrica (PubMed 20070280), 2010

    Kamin et al. dose-finding: 400 patients; 60 mg and 90 mg daily tablets better than placebo on BSS; 30 mg not clearly effective; Ukrainian centers.

  5. Effects of Pelargonium sidoides extract EPs 7630 on acute cough and quality of life - a meta-analysis of randomized, placebo-controlled trials

    Multidisciplinary Respiratory Medicine (PubMed 36051888), 2022

    Kardos et al., including Schwabe authors: 11 trials, 2,195 participants; complete cough remission at day 7 in 26.0% vs 6.3% of adults and 18.0% vs 5.5% of children with acute bronchitis.

  6. Pelargonium sidoides extract (EPs® 7630) versus usual care for acute bronchitis in Swiss primary care (PHYTOBRONCH): a pragmatic, open-label, randomised controlled trial

    npj Primary Care Respiratory Medicine (PubMed 42014704), 2026

    Bourqui et al.: 332 adults; no difference in time to 50% symptom reduction; antibiotic use 17.4% vs 25.2% (not significant); mild adverse events 32.3% vs 21.5%; no competing interests declared.

  7. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial

    Explore (PubMed 18005909), 2007

    Lizogub et al.: 103 adults, 30 drops (1.5 ml) three times daily for up to 10 days; 78.8% vs 31.4% clinically cured at day 10; 6.9 vs 8.2 days off work.

  8. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained?

    Regulatory Toxicology and Pharmacology (PubMed 22381150), 2012

    Teschke et al.: in none of 15 reported liver cases was pelargonium a highly probable or probable cause; confounding diagnoses and poor data quality.

  9. European Union herbal monograph on Pelargonium sidoides DC; Pelargonium reniforme Curt., radix (Revision 2)

    European Medicines Agency, Committee on Herbal Medicinal Products (EMA/HMPC/648100/2022), 2024

    Adopted 29 May 2024: traditional use only for common cold symptoms; liquid and dry extract doses from age 3, liquids only under 6; see a doctor after one week; stop if liver signs; not recommended in pregnancy or breastfeeding.

  10. Assessment report on Pelargonium sidoides DC; Pelargonium reniforme Curt., radix (Revision 2)

    European Medicines Agency, Committee on Herbal Medicinal Products (EMA/HMPC/765656/2022), 2024

    Critique of bronchitis trials (clinically relevant BSS thresholds not met); BfArM liver reports; allergy reports; traditional-use conclusion.

  11. Cough (acute): antimicrobial prescribing (NG120): recommendations

    National Institute for Health and Care Excellence (NICE), 2019

    Acute cough usually lasts 3–4 weeks; pelargonium listed as self-care from age 12 with limited evidence of some benefit; when to seek help; antibiotics not routinely offered for acute bronchitis.

  12. Cough (acute): antimicrobial prescribing (NG120): summary of the evidence

    National Institute for Health and Care Excellence (NICE), 2019

    Committee discussion of Timmer 2013 and Wagner 2015: some evidence P. sidoides reduces cough in acute bronchitis; liquid more beneficial than tablets; gastrointestinal adverse events; not recommended under 12.

  13. Cough

    NHS, 2023

    Coughs usually clear within 3–4 weeks; pelargonium named for ages 12 and over with limited evidence; see a GP for a cough over 3 weeks; urgent help for chest pain, breathing difficulty, or coughing blood.

  14. Kaloba Pelargonium Cough & Cold Relief Syrup: patient information leaflet

    Schwabe Pharma UK / MHRA THR 05332/0006, 2015

    EPs 7630 syrup; ages 12+ 7.5 ml three times daily, ages 6–12 5 ml; not under 6; not in pregnancy, breastfeeding, or severe liver disease; stop for yellowing, dark urine, or unusual tiredness; see a doctor if no improvement in one week.

Other herbs reviewed for cough & sore throat

All evidence reviews →